KMC Speciality

Which are the latest news on KMC Speciality?

Why is KMC Speciality Hospitals (India) Ltd falling/rising?

As of 05-Sep, KMC Speciality Hospitals (India) Ltd's stock price has risen to 138.25, reflecting a 0.29% increase. This upward trend is supported by strong performance against the sector, consistent gains over recent days, and increased investor participation.

As of 05-Sep, KMC Speciality Hospitals (India) Ltd is experiencing a rise in its stock price, currently at 138.25, with a change of 0.4 (0.29%) upward. This positive movement can be attributed to several factors. <BR><BR>Firstly, the stock has outperformed the sector by 1.55% today and has shown consistent gains over the past two days, accumulating a total return of 3.79% during this period. Additionally, KMC Speciality is trading above its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a strong upward trend.<BR><BR>Moreover, there has been a notable increase in investor participation, with a delivery volume of 70.75k on September 3, which is 11.63% higher than the 5-day average delivery volume. This suggests growing interest and confidence among investors in the stock. The liquidity of the stock is also favorable, as it is liquid enough for trades of Rs 0.03 crore based on 2% of the 5-day average traded value.<BR><BR>Overall, these factors contribute to the rising price of KMC Speciality Hospitals (India) Ltd, reflecting a positive market sentiment towards the company.

Who are in the management team of KMC Speciality?

The management team of KMC Speciality includes S Chandrakumar (Executive Chairman), Selvaraj Manivannan (Managing Director), and several non-executive and independent directors, along with Sushma K as Company Secretary. This diverse team provides both leadership and oversight for the company.

The management team of KMC Speciality includes the following individuals:<BR><BR>1. **S Chandrakumar** - Executive Chairman & Whole-Time Director<BR>2. **Selvaraj Manivannan** - Managing Director<BR>3. **A Krishnamoorthy** - Non-Executive & Independent Director<BR>4. **S Chenthilkumar** - Non-Executive & Independent Director<BR>5. **N Bala Baskar** - Non-Executive & Independent Director<BR>6. **N Jeyanthei** - Non-Executive & Independent Director<BR>7. **T Senthil Kumar** - Non-Executive & Non-Independent Director<BR>8. **Sushma K** - Company Secretary & Compliance Officer<BR>9. **S Vijayabaskaran** - Non-Executive Director<BR><BR>This team brings a mix of executive leadership and independent oversight to the company.

What does KMC Speciality do?

KMC Speciality Hospitals (India) Ltd is a micro-cap company in the hospital industry, reporting net sales of 92 Cr and a net profit of 17 Cr for June 2026. The company has a market cap of INR 2,239 Cr and key financial metrics include a P/E ratio of 40.00 and a return on equity of 26.50%.

Overview: <BR>KMC Speciality Hospitals (India) Ltd operates in the hospital industry and is categorized as a micro-cap company.<BR><BR>History: <BR>The company was originally incorporated as 'Advanced Medical Care Private Limited' in 1982, converted to a Public Limited Company in 1988, and underwent name changes to 'Seahorse Hospitals Limited' in 1995 and to 'KMC Speciality Hospitals (India) Limited' in 2008. The latest quarterly results reported net sales and profit for June 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 92 Cr (Quarterly Results - Jun 2026) <BR>Most recent Net Profit: 17 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 2,239 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 40.00 <BR>Industry P/E: 67 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.14 <BR>Return on Equity: 26.50% <BR>Price to Book: 10.71 <BR><BR>Contact Details: <BR>Address: 6 Royal Road, Cantonment Trichy Tamil Nadu : 620001 <BR>Phone: 91-431-4077777 <BR>Email: cs.kmcshil@kauveryhospital.com <BR>Website: http://www.kmcspecialityhospital.in

Who are the peers of the KMC Speciality?

KMC Speciality's peers include Kovai Medical, Jeena Sikho, Artemis Medicare, Indrapr.Medical, Dr Agarwal's Eye, Shalby, GPT Healthcare, Unihealth Hosp, and Chandan Healthca. KMC Speciality has the highest 1-year return at 97.77%, significantly outperforming its peers.

Peers: The peers of KMC Speciality are Kovai Medical, Jeena Sikho, Artemis Medicare, Indrapr.Medical, Dr Agarwal's Eye, Shalby, GPT Healthcare, Unihealth Hosp, and Chandan Healthca.<BR><BR>Quality Snapshot: Excellent management risk is observed at Kovai Medical and GPT Healthcare, while Average management risk is found at Jeena Sikho, Artemis Medicare, Indrapr.Medical, Dr Agarwal's Eye, Unihealth Hosp, Chandan Healthca, and KMC Speciality. Below Average management risk is noted at Shalby. Growth is Excellent at Jeena Sikho and Unihealth Hosp, Good at Artemis Medicare, Indrapr.Medical, and Dr Agarwal's Eye, Average at KMC Speciality, and Below Average at Kovai Medical and Shalby. Capital Structure is Excellent at Jeena Sikho, Indrapr.Medical, and GPT Healthcare, Good at Kovai Medical, Shalby, and Chandan Healthca, and Average at Dr Agarwal's Eye.<BR><BR>Return Snapshot: KMC Speciality has the highest 1-year return at 97.77%, while Jeena Sikho has the lowest at -27.85%. KMC Speciality's return significantly outperforms all its peers. Additionally, Shalby and Indrapr.Medical have negative six-month returns.

How big is KMC Speciality?

As of 31st August, KMC Speciality Hospitals (India) Ltd has a market capitalization of 2,239.00 Cr and reported net sales of 330.99 Cr and net profit of 55.77 Cr over the latest four quarters.

As of 31st August, <BR><BR>Market Cap: KMC Speciality Hospitals (India) Ltd has a market capitalization of 2,239.00 Cr, classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 330.99 Cr, while the sum of Net Profit for the same period is 55.77 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the latest annual data is March 2025. Shareholder's Funds stand at 164.33 Cr, and Total Assets are valued at 286.00 Cr.

Should I buy, sell or hold KMC Speciality Hospitals (India) Ltd?

Are KMC Speciality Hospitals (India) Ltd latest results good or bad?

KMC Speciality Hospitals (India) Ltd reported strong Q4 FY26 results, with a net profit of ₹14.63 crore (up 223.67% year-on-year) and revenue growth of 34.99% to ₹82.25 crore, marking the highest quarterly revenue in its history. Overall, the results are very good, indicating robust growth and improved operational efficiency.

KMC Speciality Hospitals (India) Ltd has reported impressive results for Q4 FY26, indicating a strong performance. The company achieved a net profit of ₹14.63 crore, which represents a remarkable year-on-year increase of 223.67%. Additionally, revenue grew by 34.99% year-on-year, reaching ₹82.25 crore, marking the highest quarterly revenue in the company's history.<BR><BR>The operating margin also reached an all-time high of 31.47%, reflecting a significant improvement from the previous year. This margin expansion is a positive indicator of the company's operational efficiency and ability to leverage its expanded facilities effectively. Furthermore, the return on equity (ROE) stands at a healthy 20.10%, demonstrating strong capital efficiency.<BR><BR>Overall, KMC Speciality's latest results are very good, showcasing robust growth in both revenue and profitability, along with improved operational metrics. The company's performance suggests it is well-positioned for continued success in the healthcare sector.

When is the next results date for KMC Speciality Hospitals (India) Ltd?

The next results date for KMC Speciality Hospitals (India) Ltd is 29 May 2026.

The next results date for KMC Speciality Hospitals (India) Ltd is scheduled for 29 May 2026.

Is KMC Speciality technically bullish or bearish?

As of November 21, 2025, the trend is mildly bullish due to daily moving averages, but mixed signals from weekly and monthly indicators suggest underlying weaknesses.

As of 21 November 2025, the technical trend has changed from bullish to mildly bullish. The current stance is mildly bullish, driven primarily by the daily moving averages indicating bullish momentum. However, the weekly MACD and KST are bullish, while the monthly MACD and KST are bearish, suggesting mixed signals across different time frames. The weekly RSI is bearish, which adds to the cautious outlook. Overall, the indicators reflect a mildly bullish sentiment, but with some underlying weaknesses, particularly in the longer-term monthly data.

Is KMC Speciality overvalued or undervalued?

As of November 13, 2025, KMC Speciality is considered undervalued with a PE Ratio of 41.88 and an attractive valuation compared to peers like Apollo Hospitals and Max Healthcare, while also outperforming the Sensex with a 1-week return of 12.88%.

As of 13 November 2025, KMC Speciality has moved from a fair to an attractive valuation grade. The company is currently considered undervalued, especially when compared to its peers in the hospital industry. Key ratios include a PE Ratio of 41.88, an EV to EBITDA of 19.70, and a ROE of 18.51%. <BR><BR>In comparison to peers, Apollo Hospitals has a significantly higher PE Ratio of 64.07, while Max Healthcare is even more expensive at 88.67. This suggests that KMC Speciality offers a more favorable valuation relative to its competitors. Additionally, KMC's recent stock performance has outpaced the Sensex, with a 1-week return of 12.88% compared to the Sensex's 1.40%, reinforcing the attractiveness of its current valuation.

How has been the historical performance of KMC Speciality?

KMC Speciality has shown steady growth in net sales and total operating income, reaching 231.60 Cr in March 2025, but faced declines in profit metrics and increased liabilities, indicating potential profitability challenges. Cash flow from operations improved, contributing to a stronger cash position despite negative investing cash flow.

Answer:<BR>The historical performance of KMC Speciality shows a steady growth in net sales, reaching 231.60 Cr in March 2025, up from 177.18 Cr in March 2024 and 155.76 Cr in March 2023. Total operating income has followed a similar upward trend, increasing to 231.60 Cr in March 2025 from 177.18 Cr in the previous year. The company's total expenditure, excluding depreciation, also rose to 174.71 Cr in March 2025, compared to 129.79 Cr in March 2024. Operating profit, excluding other income, improved to 56.89 Cr in March 2025, while profit before tax decreased to 31.60 Cr from 40.56 Cr in March 2024. Profit after tax also saw a decline to 21.43 Cr in March 2025 from 30.38 Cr in March 2024. The earnings per share (EPS) decreased to 1.31 in March 2025 from 1.86 in March 2024. <BR><BR>In terms of assets and liabilities, total assets increased to 286.00 Cr in March 2025 from 263.72 Cr in March 2024, while total liabilities also rose to 286.00 Cr from 263.72 Cr. The company's long-term borrowings increased to 72.33 Cr in March 2025, up from 63.85 Cr in March 2024. Cash flow from operating activities improved to 57.00 Cr in March 2025, compared to 38.00 Cr in March 2024, while cash flow from investing activities showed a negative trend at -50.00 Cr in March 2025. The closing cash and cash equivalents increased to 9.00 Cr in March 2025 from 4.00 Cr in March 2024, indicating a positive cash position despite the fluctuations in profit metrics.<BR><BR>Breakdown:<BR>KMC Speciality has demonstrated consistent growth in net sales, which rose from 102.64 Cr in March 2021 to 231.60 Cr in March 2025. This growth is reflected in the total operating income, which also increased significantly over the years. However, the total expenditure has risen in tandem, leading to an operating profit of 56.89 Cr in March 2025, a notable increase from previous years. Despite this, profit before tax and profit after tax saw declines in March 2025 compared to the previous year, indicating potential challenges in maintaining profitability. The company's total assets and liabilities have both increased, with long-term borrowings rising significantly, suggesting increased leverage. Cash flow from operating activities has improved, contributing to a stronger cash position, even as cash flow from investing activities remains negative. Overall, while KMC Speciality has shown growth in sales and operating income, profitability metrics and rising liabilities warrant close attention.

Who are the top shareholders of the KMC Speciality?

The top shareholder of KMC Speciality is Sri Kauvery Medical Care (India) Limited, holding 75%. D Chitra is the largest individual investor with 1.36%, while individual investors collectively own 22.03% of the shares.

The top shareholders of KMC Speciality are primarily the promoters, with Sri Kauvery Medical Care (India) Limited holding the largest stake at 75%. In terms of public shareholders, D Chitra is the highest individual investor with a holding of 1.36%. Additionally, individual investors collectively hold 22.03% of the shares. There are also four mutual fund schemes and one foreign institutional investor (FII) involved, but their holdings are minimal.

Has KMC Speciality declared dividend?

No Dividend History Available